عرض بسيط للتسجيلة

المؤلفHasan, Adria
المؤلفKhan, Naushad Ahmad
المؤلفUddin, Shahab
المؤلفKhan, Abdul Q.
المؤلفSteinhoff, Martin
تاريخ الإتاحة2025-04-16T05:09:34Z
تاريخ النشر2024-01-31
اسم المنشورSeminars in Cancer Biology
المعرّفhttp://dx.doi.org/10.1016/j.semcancer.2023.12.001
الرقم المعياري الدولي للكتاب1044579X
معرّف المصادر الموحدhttps://www.sciencedirect.com/science/article/pii/S1044579X2300158X
معرّف المصادر الموحدhttp://hdl.handle.net/10576/64218
الملخصCancer progression is a multifaceted process that entails several stages and demands the persistent expression or activation of transcription factors (TFs) to facilitate growth and survival. TFs are a cluster of proteins with DNA-binding domains that attach to promoter or enhancer DNA strands to start the transcription of genes by collaborating with RNA polymerase and other supporting proteins. They are generally acknowledged as the major regulatory molecules that coordinate biological homeostasis and the appropriate functioning of cellular components, subsequently contributing to human physiology. TFs proteins are crucial for controlling transcription during the embryonic stage and development, and the stability of different cell types depends on how they function in different cell types. The development and progression of cancer cells and tumors might be triggered by any anomaly in transcription factor function. It has long been acknowledged that cancer development is accompanied by the dysregulated activity of TF alterations which might result in faulty gene expression. Recent studies have suggested that dysregulated transcription factors play a major role in developing various human malignancies by altering and rewiring metabolic processes, modifying the immune response, and triggering oncogenic signaling cascades. This review emphasizes the interplay between TFs involved in metabolic and epigenetic reprogramming, evading immune attacks, cellular senescence, and the maintenance of cancer stemness in cancerous cells. The insights presented herein will facilitate the development of innovative therapeutic modalities to tackle the dysregulated transcription factors underlying cancer.
راعي المشروعThe study was supported by grant from the Medical Research Center (to Khan AQ; Grants MRC#0122-297, IRGC#06-NI-19-189), Hamad Medical Corporation, Doha, State of Qatar.
اللغةen
الناشرElsevier
الموضوعEmerging cancer hallmarks, transcription factors
Metabolic reprogramming, epigenetic reprogramming
Senescence
Therapeutic response
العنوانDeregulated transcription factors in the emerging cancer hallmarks
النوعArticle
الصفحات31-50
رقم المجلد98
ESSN1096-3650
dc.accessType Open Access


الملفات في هذه التسجيلة

Thumbnail

هذه التسجيلة تظهر في المجموعات التالية

عرض بسيط للتسجيلة